岭南急诊医学杂志
嶺南急診醫學雜誌
령남급진의학잡지
LINGNAN JOURNAL OF EMERGENCY MEDICINE
2015年
2期
88-90
,共3页
李晚泉%方长庚%曾小茹%涂军荣%郑晓东%梁建光
李晚泉%方長庚%曾小茹%塗軍榮%鄭曉東%樑建光
리만천%방장경%증소여%도군영%정효동%량건광
急性心力衰竭%重组人脑利钠肽%心血管事件%左心室功能
急性心力衰竭%重組人腦利鈉肽%心血管事件%左心室功能
급성심력쇠갈%중조인뇌리납태%심혈관사건%좌심실공능
acute heart failure%recombinant human brain natriuretic%cardiovascular events%left ventricular function
目的:探讨重组人脑利钠肽(rhBNP)对急性重症心力衰竭患者预后的影响。方法:将2010年8月至2013年8月收治的急性重症心力衰竭患者237例随机分为观察组(n=120)和对照组(n=117),对照组给予异舒吉治疗,观察组给予 rhBNP 治疗,比较两组气促缓解时间、住院时间及治疗前后尿量、液体入量、左室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)、左心室舒张末期内径(LVDd)、N 末端 B 型利钠肽原(NT-proBNP)的变化。结果:治疗后,观察组24 h 尿量、LVEF明显高于对照组(P<0.05);观察组呼吸困难缓解时间、住院时间、NT-proBNP 水平、不良心血管事件发生率均明显低于对照组(P<0.05)。结论:rhBNP能有效改善急性重症心力衰竭患者左心室功能,缩短气促缓解时间、住院时间,降低不良心血管事件发生率。
目的:探討重組人腦利鈉肽(rhBNP)對急性重癥心力衰竭患者預後的影響。方法:將2010年8月至2013年8月收治的急性重癥心力衰竭患者237例隨機分為觀察組(n=120)和對照組(n=117),對照組給予異舒吉治療,觀察組給予 rhBNP 治療,比較兩組氣促緩解時間、住院時間及治療前後尿量、液體入量、左室射血分數(LVEF)、每搏輸齣量(SV)、心髒指數(CI)、左心室舒張末期內徑(LVDd)、N 末耑 B 型利鈉肽原(NT-proBNP)的變化。結果:治療後,觀察組24 h 尿量、LVEF明顯高于對照組(P<0.05);觀察組呼吸睏難緩解時間、住院時間、NT-proBNP 水平、不良心血管事件髮生率均明顯低于對照組(P<0.05)。結論:rhBNP能有效改善急性重癥心力衰竭患者左心室功能,縮短氣促緩解時間、住院時間,降低不良心血管事件髮生率。
목적:탐토중조인뇌리납태(rhBNP)대급성중증심력쇠갈환자예후적영향。방법:장2010년8월지2013년8월수치적급성중증심력쇠갈환자237례수궤분위관찰조(n=120)화대조조(n=117),대조조급여이서길치료,관찰조급여 rhBNP 치료,비교량조기촉완해시간、주원시간급치료전후뇨량、액체입량、좌실사혈분수(LVEF)、매박수출량(SV)、심장지수(CI)、좌심실서장말기내경(LVDd)、N 말단 B 형리납태원(NT-proBNP)적변화。결과:치료후,관찰조24 h 뇨량、LVEF명현고우대조조(P<0.05);관찰조호흡곤난완해시간、주원시간、NT-proBNP 수평、불양심혈관사건발생솔균명현저우대조조(P<0.05)。결론:rhBNP능유효개선급성중증심력쇠갈환자좌심실공능,축단기촉완해시간、주원시간,강저불양심혈관사건발생솔。
Objective:To explore the effect of recombinant human brain natriuretic peptide (rhBNP)on the prognosis of patients with acute severe heart failure. Methods:237 patients with acute severe heart failure were randomly divided into observation group (n=120) and control group (n=117) treated by rhBNP and isosorbide dinitrate respectively from Aug 2010 to Aug 2013.The dyspnea remission time , hospitalization time and amount of urine before and after the treatment, the intake of liquid, left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac index (CI), left ventricular end diastolic diameter (LVDd), N terminal B type natriuretic peptide (NT-proBNP) changes were compared between the two groups. Results: Compared with the control group after the treatment, 24h urine volume and LVEF were significantly higher in the observation group (both P < 0.05), and the dyspnea remission time , hospitalization time , NT-proBNP levels , adverse cardiovascular event rates were significantly lower in the observation group (all P < 0.05). Conclusion:It can effectively improve left ventricular function, shorten the dyspnea remission time , hospitalization time , reduce the incidence of adverse cardiovascular events for patients with severe acute heart failure treated by rhBNP.